Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

mAB

Financiado

Cerrado

many(Anti)Bodies

Many of the exceptional breakthroughs in pharmaceutics require the collective and interdisciplinary effort of the scientific community to overcome challenges and shortcomings involved in optimizing the formulation of the final pro... ver más

30/11/2025

LUNDS UNIVERSITET

207K€

Presupuesto del proyecto: 207K€

Líder del proyecto

LUNDS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-20

HORIZON-MSCA-2022-PF-01-01: MSCA Postdoctoral Fellowships 2022 Expected Outcome:

I+D

Cerrada

0% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

LUNDS UNIVERSITET

206.89K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 32 meses Fecha Inicio: 2023-03-20
Fecha Fin: 2025-11-30

Líder del proyecto

LUNDS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 207K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Many of the exceptional breakthroughs in pharmaceutics require the collective and interdisciplinary effort of the scientific community to overcome challenges and shortcomings involved in optimizing the formulation of the final product. Monoclonal antibodies, for instance, have been found to be highly effective for the treatment of various immunological and allergic diseases as well as for cancer treatments thanks to their high specificity. On the other hand, they typically present high viscosities in concentrated solutions, dramatically altering their flow properties. The direct consequence is the difficulty in preparing stable solutions suitable for subcutaneous self-administration which, compared to intravenous infusion, would be advantageous in terms of patient compliance and adherence to the treatment, and reduced healthcare costs. Currently, a univocal framework providing microscopic interpretation to the enhanced viscosity is missing. With my proposal many(Anti)Bodies, I aim to address this issue by putting forward an interdisciplinary approach which exploits soft matter and colloidal science to investigate the molecular origin of the observed macroscopic behavior in antibody solutions. By combining numerical simulations with experiments, I will first design an accurate single-molecule model that accounts for the anisotropic shape of the antibody and include all relevant ingredients that determine intermolecular interactions. Therefore, through advanced computational techniques, I will be able to bring the current understanding of the antibody collective behavior and rheological properties to a new level, by shedding light on their dynamics and self-association in crowded environments. With the direct collaboration of pharmaceutical industries, my proposal will ultimately guide the formulation of novel antibody-based biologics and inspire future studies where the features of the antibody are designed according to the desired solution properties.

Conecta tu I+D

Entra hoy

Forgot your password?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores